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Background: Glutamine (Gln) supplementation during concurrent chemoradiotherapy (C-CRT) effectively reduces
the incidence and severity of acute radiation-induced esophagitis (RIE). However, there are concerns that Gln might
stimulate tumor growth, and therefore negatively impact the outcomes of anticancer treatment. We retrospectively
investigated the effect of co-administration of oral Gln during C-CRT on survival outcomes of patients with stage
IIIB non-small cell lung carcinoma (NSCLC). We additionally evaluated role of oral Gln in preventing C-CRT-induced
weight change, acute and late toxicities.
Methods: The study included 104 patients: 56 (53.8%) received prophylactic powdered Gln (Gln+) orally at a dose
of 10 g/8 h and 48 (46.2%) did not receive Gln (Gln-) and served as controls. The prescribed radiation dose to the
planning target volume was 66 Gy in 2-Gy fractions. Primary endpoints of progression-free survival (PFS), local/
regional progression-free survival (LRPFS), and overall survival (OS) were correlated with status of Gln
supplementation.
Results: Oral Gln was well tolerated except for mild nausea/vomiting in 14 (25.0%) patients. There was no
C-CRT-related acute or late grade 4–5 toxicity. Administration of Gln was associated with a decrease in the
incidence of grade 3 acute radiation-induced esophagitis (RIE) (7.2% vs. 16.7% for Gln+ vs. Gln-; p=0.02) and late-RIE
(0% vs. 6.3%; p=0.06), a reduced need for unplanned treatment breaks (7.1% vs. 20.8%; p=0.04), and reduced
incidence of weight loss (44.6% vs. 72.9%; p=0.002). At a median follow-up of 24.2 months (range 9.2-34.4) the
median OS, LRPFS, and PFS for Gln+ vs. Gln- cohorts were 21.4 vs. 20.4 (p=0.35), 14.2 vs.11.3 (p=0.16), and 10.2 vs.
9.0 months (p=0.11), respectively.
Conclusion: In our study, supplementation with Gln during C-CRT had no detectable negative impact on tumor
control and survival outcomes in patients with Stage IIIB NSCLC. Furthermore, Gln appeared to have a beneficial
effect with respect to prevention of weight loss and unplanned treatment delays, and reduced the severity and
incidence of acute- and late-RIE.
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Complications related to concurrent chemoradiotherapy
(C-CRT) such as acute radiation-induced esophagitis
(ARIE) may cause significant morbidity and unplanned
treatment delays in patients with locally advanced non-
small cell lung carcinoma (LA-NSCLC). Such complica-
tions not only impact the quality of life but also reduce
the ability to escalate the dose of radiotherapy (RT) to
more effective levels, resulting in potential reductions in
tumor control and survival rates. Improvements in tar-
get definition and the advent of sophisticated RT techni-
ques, combined with elimination of elective irradiation
of clinically uninvolved lymphatics, have significantly
reduced the volume of normal tissue exposed to high-
dose radiation with a resultant reduction in incidence
and severity of treatment-related toxicity [1]. However,
because of the need to irradiate subclinical tumor exten-
sion, normal tissue toxicity and its consequences likely
will remain a challenge for the foreseeable future [2].
Pharmacologic radioprotection can efficiently prevent,
or at least reduce, the incidence and/or severity of acute
radiation-induced esophagitis (ARIE) and related com-
plications during C-CRT of LA-NSCLC. One agent with
potential radioprotective properties is glutamine (Gln),
the primary oxidative fuel of the gut epithelium that is
necessary for maintenance of its structural integrity
[3,4]. Although Gln is continuously provided by skeletal
muscles during hypercatabolic states such as cancer,
over time marked Gln depletion develops that cannot be
overcome by increased synthesis [4]. This results in
compromised acid–base balance, immune functions, and
epithelial integrity in the gut [5]. Additionally, because
of its antioxidant activity in normal tissues, depletion of
glutathione (GSH), a by-product of Gln metabolism,
may increase the extent of tissue damage caused by C-
CRT [3,6,7]. In this context, exogenous Gln supplemen-
tation not only normalizes Gln levels in the body but
also selectively increases GSH levels in normal tissue,
which may explain its selective radioprotective function
[3,6-8]. Two recent studies, including one from our in-
stitution, revealed a beneficial role of oral Gln in the re-
duction of ARIE incidence and severity, as well as
maintenance of body weight, in LA-NSCLC patients
treated with C-CRT [9,10].
It is important to investigate the effect of any agent
that reduces treatment-related toxicities on tumor tissue.
As an example, amifostine, which is a strong radiopro-
tector, was found to have no detrimental effects on sur-
vival outcome in a recent meta-analysis by Bourhis et al.
[11], suggesting no tumor protection or growth stimulat-
ing action. On the contrary, erythropoietin, which has
been used successfully for stimulation of erythropoiesis
in various cancers, negatively impacted survival out-
comes for most tumor types [12]. Considering these twoconflicting results of two agents, commonly practiced in
radiation oncology clinics, because growth of various cell
lines of tumor and non-tumor origin is a function of Gln
availability [13-15], there is increasing concern that Gln
might stimulate tumor growth and therefore negatively
impact outcomes of anticancer treatment. This issue has
never been addressed in the setting of NSCLC. There-
fore, in this retrospective analysis, we comparatively
assessed the impact of Gln supplementation during C-
CRT on survival outcomes in LA-NSCLC patients. We
additionally evaluated role of oral Gln in preventing C-
CRT-induced weight change, acute and late toxicities.Methods
Study subjects
The database maintained by our institution was retro-
spectively searched to identify all patients with LA-
NSCLC who had undergone C-CRT between January
2008 and December 2010. Inclusion criteria were: histo-
pathologically proven NSCLC, stage IIIB disease by 18F-
fluorodeoxyglucose positron emission tomography (FDG
PET-CT), age ≥18 and <70, Karnofsky Performance Sta-
tus (KPS) ≥70, available treatment charts and hospital
computerized data, RT data sets for dosimetric calcula-
tions, no prior history of thoracic RT (TRT) or chemo-
therapy, no contraindication for C-CRT, no pre-
treatment dysphagia or ingestion difficulties, body mass
index (BMI) ≥18 kg/m2, and no dietary supplementation
except for Gln in the prescribed dose and schedule. The
study population contained 104 patients who met the
above criteria.
The study was approved by the institutional review
board of Baskent University before collection of patient
information and was conducted according to the princi-
ples of the Declaration of Helsinki and the rules of Good
Clinical Practice.Concurrent chemoradiotherapy
In our department, FDG-PET-CT fusion-based three-
dimensional treatment planning is the standard of care for
LA-NSCLC patients. Target volume definition, dose speci-
fication, and normal tissue tolerance limits for eligible
patients were as described elsewhere [10]. Briefly, TRT
was administered through anteroposterior-posteroanterior
(AP-PA) portals with individualized multi-leaf collimator
blocks for initial planning target volume (PTV1) up to 46
Gy, followed by an off-spinal cord oblique boost dose of
up to 66 Gy for PTV2. All patients received daily TRT for
5 days a week with 2 Gy per fraction using high energy
linear accelerators and concurrent treatment with one of
the two following chemotherapy combinations: CD, cis-
platin (80 mg/m2) and docetaxel (80 mg/m2), on days 1,
22, and 43 (n=49); or CV, cisplatin (80 mg/m2) and
Table 1 Radiation Therapy Oncology Group (RTOG) acute
radiation-induced esophageal morbidity scoring criteria
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cycles (n=55).Grade Description
0 No change
1 Mild dysphagia or odynophagia, requiring topical
anesthetic, non-narcotic agents, or soft diet
2 Moderate dysphagia or odynophagia, requiring
narcotic agents or liquid diet
3 Severe dysphagia or odynophagia with dehydration
or weight loss (>15% of pretreatment baseline),
requiring nasogastric feeding
4 Complete stricture, ulceration, perforation or fistula
5 DeathGlutamine supplementation
Our current institutional policy is to recommend
prophylactic Gln supplementation for all patients sched-
uled to undergo TRT. We prefer to use oral Gln powder
to reduce the incidence and severity of ARIE. Fifty-six
patients (53.8%) received powdered Gln (Nestle Nutri-
tion, Istanbul, Turkey) at a dose of 10 g/8 h orally in
water or fruit juice, starting 1 week before TRT and con-
tinuing for 2 weeks after completion of RT. The
remaining 48 patients (46.2%), who did not receive Gln
due to economic reasons or patients’ self-choice, served
as controls. Based on institutional standards, patients re-
ceiving Gln were followed by experienced nurses for ad-
herence to protocol, general nutritional status, and
adverse events throughout the treatment period. The
dose of 30 g/day was selected based on available lit-
erature, which reported its efficacy in reducing the
incidence and severity of ARIE and weight loss in
LA-NSCLC patients treated with C-CRT [9,10] and in
lowering the incidence of grade 2–4 mucositis in
patients treated with cytotoxic chemotherapy [16,17].
Patients who did not use Gln were nourished with diets
that were achievable based on their socioeconomic sta-
tus to improve their nutritional status.Patient evaluation and toxicity scoring
For each patient, we calculated weight change (WC),
percent WC (PWC), and body mass index (BMI) change
between baseline and post-treatment measures using
available chart records. Weight change, the absolute
difference between pre- and post-treatment weight mea-
sures, is a parameter that is independent of pre-
treatment weight and has the potential to underestimate
the value of pre-treatment body mass [18]. Therefore,
we also calculated weight change as a percentage relative
to pre-treatment weight (PWC). Nausea and vomiting
was considered Gln-induced only if reported within the
1-week period of Gln administration before commence-
ment of C-CRT, and graded according to RTOG scoring
[19]. All patients were examined at weekly intervals for
ARIE incidence and weight changes during C-CRT.
ARIE was graded by a radiation oncologist according to
RTOG-ARIE scoring criteria [19], and the reported
grade of ARIE reflected the worst grade observed
(Table 1). The calculated and reported data were used
for intra- and intergroup comparisons. After completion
of C-CRT, patients were examined at weekly intervals
for the first month to allow for the possibility of an early
“esophagitis peak” and bimonthly thereafter.Response assessment and follow-up
Treatment response was assessed by re-staging FDG-
PET-CT scans from the 8-week post-C-CRT follow-up
according to EORTC-1999 guidelines [20] (summarized
in Table 2), and at 3-month intervals thereafter. The 8-
week time interval for the first follow-up FDG-PET-CT
was arbitrarily chosen as the shortest possible time for
response assessment based on our national health insur-
ance politics, rather than on evidence-based practice.
Thereafter, patients were monitored by evaluation of
blood count/chemistry every 8–12 weeks. Additional ab-
dominal ultrasound and/or CT, chest CT, cranial mag-
netic resonance imaging, and FDG-PET-CT were
performed as indicated.Statistical methods
Statistical analyses were performed based on patient
stratification according to their Gln supplementation
status (Gln+ and Gln-). Frequency distributions were
used to describe categorical variables and mean, median,
and ranges were used for quantitative variables. Demo-
graphic features were compared between the Gln+ and
Gln- cohorts using a Chi-square test. The effects of Gln
on acute and late radiation-induced esophageal toxicity,
BMI change, WC, and PWC during treatment, and need
for hospitalization and/or treatment breaks were com-
paratively analyzed. As these issues were previously
addressed in our previous study, for this current study,
the primary endpoints were determined to be differences
in overall survival (OS), locoregional progression-free
survival (LRPFS), and progression-free survival (PFS) be-
tween the two cohorts. OS, LRPFS, and PFS were calcu-
lated as the time between the first day of C-CRT and the
date of death/last visit for OS, the date of local or re-
gional relapse or the date of death/last visit for LRPFS,
and any type of local/regional or distant progression of
disease or the date of death/last visit for PFS. Survival
analysis was performed by the Kaplan-Meier method
and the survival curves of subsets were compared with
Table 2 Proposed EORTC 1999 criteria for clinical and subclinical response assessment by PET-CT
Response Definition
Progressive metabolic disease An increase in 18FDG tumor SUV of greater than 25% within the tumor
region defined on the baseline scan, visible increase in the extent of 18FDG
tumor uptake (>20% in the longest dimension) or the appearance of new
18FDG uptake in metastatic lesions
Stable metabolic disease An increase in tumor 18FDG SUV of less than 25% or a decrease of less
than 15% and no visible increase in extent of 18FDG tumor uptake (>20% in
the longest dimension)
Partial metabolic response A reduction of a minimum of 15–25% in tumor 18FDG SUV after one cycle
of chemotherapy, and greater than 25% after more than one treatment cycle
Complete metabolic response Complete resolution of 18FDG uptake within the tumor volume so that it
was indistinguishable from surrounding normal tissue
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p-value <0.05 was considered significant.
Results
Pretreatment characteristics of patients and disease are
shown in Table 3. In general C-CRT was well tolerated
in both cohorts. The unique acute toxicities experienced
during the first week of Gln administration prior to initi-
ation of C-CRT were mild nausea in 10 (17.9%) patients
and vomiting in 4 (7.1%) patients, both of which were
successfully treated with metoclopramide. During the
course of C-CRT there was no grade ≥3 nausea or
vomiting, and the rates of grade 1–2 nausea and vomit-
ing were 32.1% and 19.6% respectively for Gln+ cohorts
and 29.2% and 16.7% for Gln- cohorts (p>0.05 for each).
No grade 4–5 ARIE was reported in Gln+ or Gln-
cohorts. As shown in Table 4, comparative analysis
revealed a significantly lower incidence of grade 3 ARIE
in the Gln+ cohort than in the Gln- cohort (7.2% vs.
16.7%; p=0.02). Diagnosis of maximum grade ARIE was
delayed by 8 days with the use of Gln (24.5 vs. 16.4 days,
p=0.001). Unplanned treatment delays, either by fre-
quency or time, were also significantly lower in the Gln+
cohort. Hospitalization was needed in 5 (4.8%) patients:
3 (6.3%) in the Gln- cohort and 2 (3.6%) in the Gln+
cohort (p=0.14), and all patients were able to complete
C-CRT with appropriate treatment and supportive mea-
sures as indicated. Over the long-term, no grade 4/5 late
esophageal toxicity (LET) was reported in either cohort.
The incidence of grade 2/3 LET was higher in the Gln-
cohort than the Gln+ cohort (12.6% vs. 3.6%), approach-
ing statistical significance (p=0.06).
Although all other supportive measures were similar
between cohorts, Gln- patients experienced significant
weight loss, negative PWC, and negative BMI change,
whereas Gln+ patients maintained or gained weight at
the end of the C-CRT course, as reflected in the PWC
and BMI measurements (Table 4).
At a median follow-up of 24.2 months (range 5.2-
37.8), 45 patients (36.9%) were alive [23 Gln+ (41.1%)
and 22 Gln- (45.8%)], and 17 (16.3%) of these were freeof disease progression [10 Gln+ (17.9%) and 7 Gln-
(14.6%)]. Analysis of response rates according to
EORTC-1999 criteria and relapse patterns revealed no
significant difference between the two cohorts (p>0.05;
Table 5). Partial response and distant relapses were the
most common response and relapse patterns in both
Gln+ and Gln- cohorts.
Median OS, LRPFS, and PFS for the entire population
were 20.9 (95% CI: 19.5-22.3), 12.7 (95% CI: 11.5-13.5),
and 9.7 months (95% CI: 9.0-10.4), respectively. Corre-
sponding 2-and 3-year survival estimates were 34.9%
and 25.4% for OS; 16.8% and 16.8% for LRPFS; and
16.1% and 16.1% for PFS, respectively. As shown in
Figure 1 and Table 6, intergroup comparisons between
Gln+ and Gln- cohorts revealed no statistically signifi-
cant differences in median 2- and 3-year OS, LRPFS,
and PFS.
Discussion
Despite the potential unpredictable disadvantages of any
retrospective analysis, in the dose and schedule utilized
here, present results showed that besides being beneficial
in prevention of weight loss, unplanned treatment
delays, severity and incidence of acute and late RIE, co-
administration of Gln during C-CRT has no detectable
negative impact on tumor control and survival outcomes
in patients with stage IIIB NSCLC.
One strategy to reduce radiation-induced normal tis-
sue toxicity is the use of protective pharmacologic agents
shortly before and/or during the course of RT/C-CRT.
Recent preclinical studies revealed that Gln, the primary
fuel of enterocytes and lymphocytes, not only plays a
crucial role in maintaining gut integrity and cellular im-
munity [3,21-24] but also protects against acute and late
radiation-induced injury by inhibiting bacterial trans-
location and stimulating production of the antioxidant
GSH [25-29]. Clinically, oral Gln reduces the incidence
and severity of RT- and/or chemotherapy-induced mu-
cosal injury at various tumor sites, including the esopha-
gus in NSCLC [9,10,30-32]. Similarly, our current
findings showed that Gln prophylaxis was associated
Table 3 Pretreatment patient and disease characteristics
Characteristic All Glutamine (+) Glutamine (−) P-value
(N=104) (N=56) (N=48)
Age (years)
Median (Range) 57.6 (33–69) 58.7 (41–69) 56.5 (33–69) 0.41
Gender (N; %)
Male 67 (64.4) 35 (62.5) 32 (66.7) 0.62
Female 37 (35.6) 21(37.5) 16 (33.3)
Histology (N; %)
Squamous cell 64 (61.5) 34 (60.7) 30 (62.5) 0.81
Adeno 40 (38.5) 22 (39.3) 18 (37.5)
KPS (N; %)
90 – 100 58 (55.8) 30 (53.6) 28 (58.3) 0.76
70 - 80 46 (44.2) 26 (46.4) 20 (41.7)
TN-stage (N; %)
T1N3 7 (6,7) 4 (7,1) 3 (6,3) 0.38
T2N3 13 (12.5) 6 (10.7) 7 (14.5)
T3N3 17 (16.3) 10 (17.8) 7 (14.5)
T4N0 11 (10.6) 6 (10.7) 5 (10.4)
T4N1 16 (15.4) 8 (14.3) 8 (16.7)
T4N2 18 (17.3) 10 (17.9) 8 (16.7)
T4N3 22 (21.2) 12 (21.5) 10 (20.9)
T-stage (N; %)
1 7 (6.7) 4 (7.1) 3 (6.3) 0.33
2 13 (12.5) 6 (10.7) 7 (14.5)
3 17 (16.3) 10 (17.8) 7 (14.5)
4 67 (64.5) 36 (64.4) 31 (64. 7)
N-stage (N; %)
0 11 (10.6) 6 (10.7) 5 (10.4) 0.58
1 16 (15.4) 8 (14.3) 8 (16.7)
2 18 (17.3) 10 (17.9) 8 (16.7)
3 59 (56.7) 32 (57.1) 25 (58.1)
Bulk of T (N; %)
≤ 3.0 cm 8 (7.7) 3 (5.4) 5 (10.4) 0.42
3.01 - 5.0 cm 15 (14.4) 8 (14.3) 7 (14.6)
5.01 - 7.0 cm 43 (41.3) 24 (42.9) 19 (39.6)
> 7.0 cm 38 (36.6) 21 (37.4) 17 (35.4)
Bulk of largest N (N; %)
≤ 2.0 cm 58 (55.8) 30 (53.7) 28 (58.3) 0.22
> 2.0 cm 46 (44.2) 26 (46.3) 20 (41.7)
Chemotherapy
Platin – docetaxel 46 (44.2) 24 (42.9) 22 (45.8) 0.79
Platin - vinorelbine 58 (55.8) 32 (57.1) 26 (54.2)
Weight (kg)
Median (range) 66.3 (50.5-87.6) 65.9 (50.5-86.8) 67.2 (54.6-87.6) 0.37
BMI (kg/m2)
Median (range) 22.1 (18.4-27.8) 21.8 (18.4-27.6) 22.3 (18.8-27.8) 0.91
Abbreviations: BMI: Body mass index; KPS: Karnofsky performance score; N: Node; T: Tumor.
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Characteristic Glutamine (+) Glutamine (−) P-
value(N=56) (N=48)
Maximum grade ARIE (N; %)
0–1 40 (71.4) 21 (43.7) 0.02
2 37.0 34.2
3 27.8 22.8
4 - 5 0 (0) 0 (0)
Grade 2–3 ARIE onset (days)
Median 24.5 16.4 0.001
Range (17 – 32) (9–23)
Treatment delay (N; %) 4 (7.1) 10 (20.8%) 0.04
Hospitalization 2 (3.6) 3 (6.3) 0.14
Weight change (N; %)
No change or gain 31 (55.4) 13 (27.1) 0.002
Loss 25 (44.6) 35 (72.9)
Weight change (kg)
Median 2.6 −3.3 < 0.001
Range (−3.1 to 7.6) (−9.7 to 2.3)
Weight change (%)
Median 3.94 −4.91 < 0.001
Range (−4.7 to 11.5) (−14.4 to 3.4)
LET (maximum grade)
2 2 (3.6) 3 (6.3) 0.06
3 0 (0) 3 (6.3)
4 - 5 0 (0) 0 (0)
Abbreviations: ARIE: Acute radiation-induced esophagitis; LET: Late esophageal toxicity.
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dence (7.2% vs.16.8%; p=0.02), and delayed onset of
maximum grade ARIE (24.5 vs. 16.4 days; p=0.001) with
no add on toxicity.
Considering its selective protective function in normal
non-cancerous tissues, ease of use, and mild and easily
manageable toxicity profile, Gln appears to be an idealTable 5 Locoregional response and relapse characteristics for
Characteristic All
(N=104)









Locoregional + distant 19 (18.3)radioprotector. However, there are concerns that Gln
may protect tumor cells, or even promote tumor growth,
when used in conjunction with anticancer treatment
[13-15]. To our knowledge, no previous clinical study
has specifically addressed the influence of Gln on tumor
control and survival outcomes when administered dur-
ing C-CRT in NSCLC patients, and the results of studiespatients with and without glutamine supplementation
Glutamine (+) Glutamine (−) P-
value(N=56) (N=48)
8 (14.3) 7 (14.5) 0.79
18 (32.1) 16 (33.4) 0.62
16 (28.6) 12 (25.0) 0.31
14 (25.0) 13 (27.1) 0.43
10 (17.9) 9 (18.8) 0.42
10 (17.9) 10 (20.8) 0.59
25 (44.6) 21 (43.7) 0.30
11 (19.6) 8 (16.7) 0.24
Figure 1 Comparative survival analyses between Gln+ and Gln- cohorts. A: Overall survival (OS); B: Progression-free Survival (PFS); C: Local
Regional Progression-free Survival (LRPFS). Solid line: Gln+; Dashed line: Gln-.
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fore, this is the first report of the effects of Gln on sur-
vival outcomes, and indirectly, tumor growth kinetics of
LA-NSCLC in the era of RT/C-CRT.
Although the fact that human tumors exhibit a 5- to
10-fold faster rate of Gln consumption than normal
healthy tissues [37-39] might suggest that supplemental
Gln would promote growth of tumor calls [13-15], Gln
did not stimulate tumor growth or negatively affect the
outcome of any type of anti-tumor treatment in this
study and previously published reports [8,21,22,40,41].
In experimental studies, Gln supplementation has re-
peatedly been shown to replete Gln stores in muscle
with no promotion of tumor growth which was proved
by absence of any notable increment in tumor DNATable 6 Survival estimates according to prophylactic
glutamine use
Survival Glutamine (+) Glutamine (−) P-
value(N=56) (N=48)
Overall
Median (months) 21.4 20.4 0.23
2-year (%) 37.0 34.2
3-year (%) 27.8 22.8
Locoregional progression free
Median (months) 11.3 14.2 0.11
2-year (%) 18.7 16.4
3-year (%) 18.7 16.4
Progression free
Median (months) 10.2 9.0 0.19
2-year (%) 17.5 14.6
3-year (%) 17.5 14.6content [8,21,22,40]. Furthermore, Fahr and colleagues
[41] demonstrated that Gln gavage and pair-fed food
combination was associated with a 30% increment in
natural killer (NK) cell activity and a 40% reduction in
tumor growth. Use of Gln in conjunction with chemo-
therapy and/or RT has been investigated in only a lim-
ited number of clinical trials. In a large randomized,
double-blind, placebo-controlled study [33], oral Gln
supplementation was associated with significantly
reduced mouth pain and, more importantly, improved
survival rates at 28 days in 193 patients undergoing au-
tologous or allogeneic bone marrow transplant. In a
similar patient group, Schloerb and Skikne [34] reported
significantly improved long-term survival with parenteral
Gln supplementation. In the setting of RT or C-CRT, the
few published studies concentrated on the radioprotec-
tive actions of Gln without considering its potential im-
pact on tumor growth and survival outcomes
[9,10,32,42,43]. Consistent with recently reported C-
CRT studies without Gln [44-49], the similar PFS,
LRPFS, and OS for Gln+ and Gln- cohorts observed in
the current study demonstrated no association between
tumor growth stimulation and high-dose Gln adminis-
tered during C-CRT of LA-NSCLC patients.
If Gln is not provided exogenously tumor cells can
successfully manipulate host metabolism to cover their
needs, therefore artificial depletion of Gln cannot stop,
or even retard, tumor growth. In fact, Gln-deprivation
increases tumor cell survival through the induction of
pro-angiogenic, pro-metastatic, pro-inflammatory, and
tumor motility factors such as VEGF, IL-8, and NF-KB
[4]. Moreover, lack of supplementary Gln can lead to
serious Gln depletion, which is closely associated with
impaired physiological functions such as disturbances in
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normal tissue GSH levels, and inhibition of bacterial
translocation, resulting in serious medical complications.
Therefore, exogenous Gln utilized here appears to im-
prove the general metabolic condition and host defense
mechanisms, and decrease the C-CRT-induced toxicity
and related detrimental effects on quality of life mea-
sures and clinical outcomes.
One important consequence of dose-limiting acute
toxicities of RT, and particularly C-CRT, in LA-NSCLC
patients is the need for unplanned treatment breaks,
which mandates reductions in doses of chemotherapy/RT
and/or prolongs the overall treatment time with the po-
tential to induce accelerated tumor repopulation [50].
Overall, any prolongation in treatment course is strongly
associated with significantly reduced efficacy of C-CRT
and therefore reduced rates of locoregional control and
survival [51]. Our study showed that Gln significantly
reduced the incidence and delayed the onset of grade ≥3
ARIE, reduced the need for unplanned treatment breaks,
and reduced hospitalization. Although our study failed
to show a significant survival advantage, further studies
with larger study cohorts and sufficient statistical power
to detect a moderate survival advantage are warranted.
The present study has several limitations. First, as for
any retrospective study, unpredictable biases may have
influenced our results. Second, heterogeneity due to in-
clusion of both adeno- and squamous cell cancer histol-
ogies, together with the limited cohort size, probably
decreased the statistical power to identify a subgroup
that may have benefited from Gln supplementation in
terms of tumor control and survival outcomes. Third, al-
though not significant statistically, the survival rates of
the Gln+ cohort were higher than those of the Gln- co-
hort at all time points, suggesting that patients who
received Gln supplementation tended to do better than
those who did not. This may be partly associated with
the small sample size and relatively short follow-up
period and should be further addressed in larger studies
with a longer follow-up period. Finally, although our in-
stitutional policy mandates arrangement of nutritional
status of patients prior to treatment, nutritional differ-
ences are strongly associated with general feeding beha-
viors and socioeconomic status and cannot easily be
controlled between the groups which may also affected
our results.
Conclusion
Our analysis showed that supplemental use of Gln dur-
ing C-CRT has no detectable negative impact on tumor
control and survival outcomes in patients with Stage IIIB
NSCLC, but rather might prevent weight loss and un-
planned treatment delays and reduce the severity and in-
cidence of acute and late RIE. However, prospectiverandomized studies with larger cohorts and statistical
power or comprehensive meta-analyses are warranted to
conclude more relevantly on this continuously discussed
specific issue of oncology.
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